Key People/Management at Adlai Nortye

Carsten Lu

Carsten Lu

Emba, CEO
Shijun Feng

Shijun Feng

Director
Show more

Adlai Nortye Office Locations

Adlai Nortye has an office in Hangzhou
Show all (1)

Adlai Nortye Financials and Metrics

Summary Metrics

Founding Date

2004

Adlai Nortye total Funding

$153 m

Adlai Nortye latest funding size

$100 m

Time since last funding

3 months ago

Adlai Nortye investors

Adlai Nortye's latest funding round in September 2020 was reported to be $100 m. In total, Adlai Nortye has raised $153 m
Show all financial metrics

Adlai Nortye Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

SecurityScorecard logo

Adlai Nortye Online and Social Media Presence

Embed Graph

Adlai Nortye News and Updates

Adlai Nortye Announces First Patient Dosed in Phase 1b Clinical Trial of AN0025 (EP4 Antagonist) in Combination with Merck's KEYTRUDA® (pembrolizumab) for Advanced Solid Tumors

NORTH BRUNSWICK, N.J., Aug. 24, 2020 /PRNewswire/ -- Adlai Nortye Ltd. ("Adlai Nortye"), a global clinical-stage biopharmaceutical company today announced that the first patient has been dosed in a phase 1b clinical trial (AN0025S0103) to evaluate AN0025, an investigational, potentially...

Adlai Nortye Presents Encouraging Phase 1b Study Data of AN0025 (an Oral EP4 Antagonist) for Locally Advanced Rectal Cancer at ESMO 2019

NORTH BRUNSWICK, New Jersey, Sept. 30, 2019 /PRNewswire/ -- Adlai Nortye Ltd. ("Adlai Nortye" or "the Company"), a global clinical-stage biopharmaceutical company dedicated to discovery, development and commercialization of new and effective drugs with a focus on Oncology, announced today...

Adlai Nortye Receives NMPA Approval for Pelareorep (AN1004) in China to Initiate Phase III Clinical Trials

HANGZHOU, China, March 21, 2019 /PRNewswire/ -- Adlai Nortye Ltd. ("Adlai Nortye"), a global clinical-stage biopharmaceutical company today announced that it has received a clearance from the National Medical Products Administration (NMPA) of China for initiating the open-label,...

Adlai Nortye Announces Clinical Collaboration with Merck to Evaluate Adlai Nortye's AN0025 (EP4 Antagonist) in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors

NORTH BRUNSWICK, N.J., Jan. 3, 2019 /PRNewswire/ -- Adlai Nortye Ltd. ("Adlai Nortye"), a global clinical-stage biopharmaceutical company today announced that it has entered into a clinical collaboration with Merck (known as MSD outside the US and Canada) to evaluate the combination of...

Adlai Nortye Opens New US Headquarters, Solidifying its Position in the Global Pharma Industry

NORTH BRUNSWICK, N.J., Sept. 25, 2018 /PRNewswire/ -- Adlai Nortye Ltd. ("Adlai Nortye" or "the Company"), a leading biopharmaceutical company dedicated to the discovery and development of innovative new treatments, announced the official opening of their new USA headquarters today during ...

Adlai Nortye eröffnet mit Blick auf globale Expansion seinen ersten internationalen Standort in den USA

BOSTON, 16. August 2018 /PRNewswire/ -- Adlai Nortye Ltd. („Adlai Nortye" oder „das Unternehmen"), ein global ausgerichtetes biopharmazeutisches Unternehmen, das eine führende Position in der Entwicklung effektiver Therapien zur Krebsbehandlung sowie für ungedeckte medizinische...
Show more

Adlai Nortye Frequently Asked Questions

  • When was Adlai Nortye founded?

    Adlai Nortye was founded in 2004.

  • Who are Adlai Nortye key executives?

    Adlai Nortye's key executives are Carsten Lu and Shijun Feng.

  • How many employees does Adlai Nortye have?

    Adlai Nortye has 36 employees.

  • Who are Adlai Nortye competitors?

    Competitors of Adlai Nortye include Pulmatrix, Humanigen and Selecta Biosciences.

  • Where are Adlai Nortye offices?

    Adlai Nortye has an office in Hangzhou.

  • How many offices does Adlai Nortye have?

    Adlai Nortye has 1 office.